Short window to halt FDA brain drain

Marty Makary is on track for Senate confirmation as FDA commissioner as soon as next week, but he’ll have little time for celebration. His immediate challenge will be to stop a steady stream of resignations from turning into a flood that sweeps away FDA’s ability to regulate innovative medicines.

FDA’s new chief of staff, Jim Traficant, has already started interviewing senior agency staff, soliciting ideas for reforms and urging them to remain at the agency. ...